New Retina Radio by Eyetube

Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Monia Reding, MD, a retina fellow at Casey Eye Institute, and Benjamin Young, MD, assistant professor of Ophthalmology at Casey Eye Institute, to talk about lasers. They share the pros and cons of slit-lamp laser and indirect, ergonomics, laser settings, difficult scenarios, and the

personal experiences that shape their practice patterns.

Could TKIs be the game-changing therapy that makes wet AMD treatment less burdensome? Dilsher Dhoot, MD, joins the show to examine the SOL-1 study, a superiority study assessing the safety, efficacy, and durability of axitinib (Axpaxli, Ocular Therapeutix) for the treatment of wet AMD.

And Carl Danzig, MD, stops by to deliver the 4.5-year data from TRUCKEE, which tells us how real-world patients with wet AMD perform when dosed with faricimab (Vabysmo, Genentech/Roche). How are patients doing after 3, 6, or even 9 doses? Stick with us to find out.

What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.

Ehsan Rahimy, MD, and Sumit Sharma, MD, examine the unmet needs in wet AMD and DME, from insufficient disease control to injection burden. They explore the emerging role of IL-6 as a driver of both conditions review, review data to support the role that IL-6 plays in both wet AMD and DME pathogenesis.  and discuss EYP-1901 (EyePoint, Inc.), a sustained-release TKI in development for wet AMD and DME.. Phase 2  clinical data from the VERONA and DAVIO 2 trials are reviewed, including visual acuity and anatomic outcomes, and the potential for reduced treatment burden.

What stands between a patient with geographic atrophy and consistent, effective treatment? And how do clinicians bridge that gap? In episode 3 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, address injection burden, insurance hurdles, and the role of patient education tools in supporting adherence. The group also weighs the potential for AI to guide treatment decisions and track progression, then works through a hypothetical case of an 82-year-old caregiver with bilateral diffuse trickling GA who is not yet motivated to pursue treatment.